gnc-077
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2024 (NCT06609187)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- UnclearBINDING AGENT
Unclear binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06755242 | Phase 1 | Jan 31, 2025 | Baili Pharmaceutical Group |
| NCT06609187 | Phase 1 | Oct 31, 2024 | Baili Pharmaceutical Group, Chinese Academy of Medical Sciences |
| NCT06612840 | Phase 1 | Oct 31, 2024 | Baili Pharmaceutical Group, Huazhong University of Science and Technology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 3 | 3 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1